Benzimidazole

Benzimidazole

SCHEMBL5554657

COc1ccc[nH]1.c1ccc2[nH]cnc2c1

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP12 P39900 1/20 0.46
IDO1 P14902 1/20 0.38
TDO2 P48775 1/20 0.38
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
QPCT Q16769 9/20 0.36
QPCTL Q9NXS2 2/20 0.35
KDM4E B2RXH2 3/20 0.35
ALDH1A1 P00352 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
GAA P10253 1/20 0.35
APOBEC3G Q9HC16 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
PDPK1 O15530 1/20 0.35
CA12 O43570 1/20 0.35
PARP1 P09874 1/20 0.35
ALOX15 P16050 1/20 0.35
CA9 Q16790 1/20 0.35
TNKS2 Q9H2K2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzimidazole SCHEMBL29218507 0.78 MMP12 (0.47) MMP12QPCTQPCTLKDM4EALDH1A1
Benzimidazole SCHEMBL6009 0.78
Benzimidazole SCHEMBL461969 0.78 SMN1; SMN2 (0.50) MMP12IDO1TDO2QPCTQPCTL
Benzimidazole SCHEMBL29408372 0.78
Benzimidazole SCHEMBL10931770 0.78 SMN1; SMN2 (0.50) MMP12IDO1TDO2QPCTQPCTL
Benzimidazole SCHEMBL29358377 0.78
Benzimidazole SCHEMBL28381628 0.77 MMP12 (0.46) MMP12IDO1TDO2QPCTQPCTL
Benzimidazole SCHEMBL5040740 0.77 KDM4E (0.47) MMP12QPCTQPCTLKDM4EALDH1A1
Benzimidazole SCHEMBL376958 0.77 MMP12 (0.46) MMP12QPCTQPCTLKDM4EALDH1A1
Benzimidazole SCHEMBL23673327 0.76 SMN1; SMN2 (0.48) MMP12IDO1TDO2QPCTQPCTL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524899-B2 Oligopeptide containing fused 6-membered ring forming complexes with double stranded dna; complexes can be used for identification of specific dsDNA sequences, inhibiting gene transcription, therapeutic for inhibiting proliferation of undesired cells or modulation of expression of specific gene CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2013-09-03 US disclosed
EP-1599474-B1 Heterocyclic oligomeric compounds for DNA recognition CALIFORNIA INST OF TECHN (US) 2013-04-24 EP disclosed
EP-1599474-A4 ALTERNATIVE HETEROCYCLES FOR DNA RECOGNITION CALIFORNIA INST OF TECHN (US) 2007-08-22 EP disclosed
EP-1599474-A2 ALTERNATIVE HETEROCYCLES FOR DNA RECOGNITION CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2005-11-30 EP disclosed
US-20050026174-A1 Alternative heterocycles for DNA recognition CALIFORNIA INSTITUTE OF TECHNOLOGY 2005-02-03 US disclosed
WO-2004078943-A2 ALTERNATIVE HETEROCYCLES FOR DNA RECOGNITION CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026174-A1 Alternative heterocycles for DNA recognition DDB1, PCNA, DNA2 MMP12 3109/4885IDO1 4424/4885TDO2 4061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.